Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Gillian M Duchesne; Henry H Woo; Madeleine King; Steven J Bowe; Martin R Stockler; Alice Ames; Catherine D'Este; Mark Frydenberg; Andrew Loblaw; Shawn Malone; Jeremy Millar; Keen Hun Tai; Sandra Turner

Journal article

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Gillian M Duchesne, Henry H Woo, Madeleine King, Steven J Bowe, Martin R Stockler, Alice Ames, Catherine D'Este, Mark Frydenberg, Andrew Loblaw, Shawn Malone, Jeremy Millar, Keen Hun Tai, Sandra Turner

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2017

DOI: 10.1016/S1470-2045(17)30426-6

University of Melbourne Researchers

Gill Duchesne Author The Sir Peter MacCallum Department of Oncology

Keen-Hun Tai Author Clinical Pathology

Grants

Funding Acknowledgements

Australian National Health and Medical Research Council and Cancer Councils, The Royal Australian and New Zealand College of Radiologists, Mayne Pharma Australia, Tolmar Australia.